Financial Updates for the Psychedelics Industry | Page 2 of 9 | Microdose

Psychedelics News

Finance

15 Aug 2023

MindMed Secures $50 Million Loan From K2 HealthVentures

MindMed secures $50 Million credit facility with K2 HealthVentures, giving company access to additional capital...

By Microdose NewsDesk

Finance

15 Aug 2023

Cybin Reports Q1 Financial Results and Business Highlights

Cybin reports first quarter financial results and business highlights, including updates on key trials....

By Microdose

Finance

4 Aug 2023

MindMed Reports Second Quarter 2023 Financial Results and Highlights

MindMed released its Q3 financial results. Highlights include enrolment in Phase 2b LSD trial, top-line results by end-of-year, and $116 million in cash....

By Microdose NewsDesk

Breaking News, Finance

1 Aug 2023

Raising Capital: Cybin Announces Public Offering

Cybin has announced a public offering for gross proceeds of US$8,250,000....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

4 Jul 2023

The Commercial Market for Legal Psychedelics: Spravato

Spravato provides insights into market potential of legal psychedelics - we take a closer look....

By Jason Najum

Finance

29 Jun 2023

Small Pharma Reports 2023 Financial Results & Business Highlights

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights...

By Jason Najum

Finance

28 Jun 2023

Cybin Reports 2023 Financial Results and Business Highlights

Cybin has reported audited financial results for fiscal year 2023 and recent business highlights....

By Microdose NewsDesk

Finance

6 Jun 2023

Compass Pathways’ Stock Soars as COMP360 Receives Patent Victory

Compass Pathways’ COMP360 has just received additional support for its IP strategy, with the US Patent and Trademark Office upholding patent protections on the compound....

By Microdose NewsDesk

Finance

31 May 2023

Cybin Announces US$30M Capital Agreement

Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result